LeMaitre Vascular (NASDAQ:LMAT) Lowered to Hold Rating by StockNews.com

LeMaitre Vascular (NASDAQ:LMAT) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a report issued on Thursday.

Other equities analysts have also issued reports about the stock. JMP Securities raised their price target on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 20th. Lake Street Capital began coverage on shares of LeMaitre Vascular in a research report on Friday, August 2nd. They issued a “buy” rating and a $105.00 price target for the company. Oppenheimer reissued an “outperform” rating and set a $93.00 price target (up previously from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Barrington Research lifted their price objective on LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a report on Friday, November 1st. Finally, Cantor Fitzgerald assumed coverage on LeMaitre Vascular in a report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 target price on the stock. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $94.57.

LeMaitre Vascular Stock Up 2.0 %

Shares of NASDAQ:LMAT opened at $107.97 on Thursday. LeMaitre Vascular has a 12-month low of $51.70 and a 12-month high of $108.09. The business has a 50 day moving average of $93.48 and a 200-day moving average of $86.61. The stock has a market cap of $2.43 billion, a PE ratio of 59.00, a P/E/G ratio of 2.54 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. The firm had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company’s revenue for the quarter was up 15.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.33 EPS. Equities research analysts expect that LeMaitre Vascular will post 1.94 earnings per share for the current year.

Insiders Place Their Bets

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of LeMaitre Vascular stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $101.47, for a total transaction of $380,512.50. Following the transaction, the director now directly owns 2,278 shares of the company’s stock, valued at approximately $231,148.66. The trade was a 62.21 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 10.79% of the company’s stock.

Institutional Trading of LeMaitre Vascular

Institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC boosted its position in shares of LeMaitre Vascular by 4.5% during the 3rd quarter. Geode Capital Management LLC now owns 542,523 shares of the medical instruments supplier’s stock valued at $50,403,000 after purchasing an additional 23,443 shares in the last quarter. M&T Bank Corp bought a new stake in LeMaitre Vascular in the third quarter worth approximately $1,551,000. Barclays PLC lifted its stake in LeMaitre Vascular by 394.5% in the third quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier’s stock valued at $3,396,000 after buying an additional 29,180 shares during the period. MML Investors Services LLC boosted its holdings in shares of LeMaitre Vascular by 2.8% during the 3rd quarter. MML Investors Services LLC now owns 7,107 shares of the medical instruments supplier’s stock worth $660,000 after buying an additional 191 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of LeMaitre Vascular during the 3rd quarter worth approximately $344,000. 84.64% of the stock is currently owned by institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.